Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodelling: results from the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART‐1) study

Aims Left ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone‐marrow‐derived, lineage‐directed, autologous cardiopoietic mesenchymal stem cells (C3BS‐CQR‐1)...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of heart failure 2017-11, Vol.19 (11), p.1520-1529
Hauptverfasser:	Teerlink, John R., Metra, Marco, Filippatos, Gerasimos S., Davison, Beth A., Bartunek, Jozef, Terzic, Andre, Gersh, Bernard J., Povsic, Thomas J., Henry, Timothy D., Alexandre, Bertrand, Homsy, Christian, Edwards, Christopher, Seron, Aymeric, Wijns, William, Cotter, Gad
Format:	Artikel
Sprache:	eng
Schlagworte:	Female Genetic Therapy - methods Heart failure Heart Failure - physiopathology Heart Failure - therapy Humans Male Mesenchymal Stem Cell Transplantation - methods Middle Aged Remodelling Stem cells Stroke Volume - physiology Treatment Outcome Ventricular Function, Left - physiology Ventricular Remodeling - physiology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Aims Left ventricular (LV) reverse remodelling is an important marker of improved outcomes in patients with advanced heart failure (HF). We examined the impact of the intramyocardial administration of bone‐marrow‐derived, lineage‐directed, autologous cardiopoietic mesenchymal stem cells (C3BS‐CQR‐1) on LV remodelling in patients with advanced HF enrolled in the CHART‐1 study. Methods and results Patients (n=351) with symptomatic advanced HF secondary to ischaemic heart disease, and reduced LV ejection fraction (LVEF
ISSN:	1388-9842 1879-0844
DOI:	10.1002/ejhf.898